{"id":"W4364353540","doi":"10.1007/s10637-022-01326-3","title":"Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Selumetinib; Nausea; Discontinuation; Vomiting; MEK inhibitor; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Population; Cancer; Phases of clinical research; Surgery; Oncology; Chemotherapy; MAPK/ERK pathway; Kinase; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002062571,0.001161114,0.00164296,0.0003254799,0.0003719088,0.0006498245,0.0005134257,0.0007117915,0.002702416],"category_scores_gemma":[0.0008475501,0.0004464136,0.0009699372,0.000270192,0.0005987358,0.0008332974,0.0002502877,0.002205942,0.0006064328],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006683911,"about_ca_system_score_gemma":0.001062267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005342476,"about_ca_topic_score_gemma":0.00192784,"domain_scores_codex":[0.9994156,0.0003020216,0.00004105827,0.00009051745,0.00007309579,0.00007757096],"domain_scores_gemma":[0.9993244,0.0001362984,0.000149718,0.00004328512,0.0000621544,0.000284064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5940633,0.136348,0.01595664,0.001294828,0.003038182,0.0004433645,0.000423766,0.003784616,0.1150165,0.0001962781,0.004805231,0.1246294],"study_design_scores_gemma":[0.2688163,0.6849177,0.03263955,0.00004394774,0.001104225,0.0004315297,0.00007881713,0.001371438,0.00740368,0.0001355291,0.003023152,0.00003424279],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993948,0.002028739,0.0004985998,0.0002451473,0.0000709051,0.00122828,0.0008200813,0.00004653202,0.001113821],"genre_scores_gemma":[0.9931069,0.001219659,0.001338509,0.0004571315,0.0001054574,0.0007821923,0.001764755,0.00002266614,0.001202747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002702416,"threshold_uncertainty_score":0.01090807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0347956569583104,"score_gpt":0.3114770306345717,"score_spread":0.2766813736762613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}